Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sensei Biotherapeutics, Inc.

0.4400
-0.0021-0.47%
Post-market: 0.45500.0150+3.41%16:15 EDT
Volume:67.89K
Turnover:30.48K
Market Cap:11.07M
PE:-0.37
High:0.4567
Open:0.4300
Low:0.4300
Close:0.4421
Loading ...

Company Profile

Company Name:
Sensei Biotherapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
1999
Employees:
28
Office Location:
1405 Research Boulevard,Suite 125,Rockville,Maryland,United States
Zip Code:
20850
Fax:
- -
Introduction:
Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. Its Tumor Microenvironment Activated Biologics platform is designed to unleash the anti-tumor potential of T cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company's pipeline includes SNS-101, SNS-103, and SNS-102, monoclonal antibodies, which are in early development stages for the treatment of solid tumors. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Directors

Name
Position
John Celebi
President and Chief Executive Officer,Director
William Ringo
Chairman
Bob Holmen
Director
Deneen Vojta
Director
James Peyer
Director
Jessie English
Director
Kristian Humer
Director
Samuel Broder
Director
Thomas Ricks
Director

Shareholders

Name
Position
John Celebi
President and Chief Executive Officer,Director
Erin Colgan
Chief Financial Officer
Edward van der Horst
Chief Scientific Officer
Patrick Gallagher
Chief Business Officer